

Index

Please note: page numbers in *italic type* indicate illustrations or tables

- ABCDEs
 cardiovascular health, 192
 of melanoma, 386
 abnormal uterine bleeding (AUB), 24–34
 acute leukemias and, 310–11
 and evaluation for
 endometrial cancer, 273
 as symptom of endometrial cancer, 49
 cancer patients, 25
 algorithms for prevention and treatment, 27, 28
 case study, 24, 34
 contraception, 33–4
 definitions, chronic and
 acute AUB, 24
 diagnosis and workup, 26–7
 epidemiology, 24–6
 etiology and risk
 factors, 25–6
 FIGO-AUB system, 24
 imaging, 26
 laboratory tests, 26
 normal menstrual cycle, 25
 physical exam findings, 26
 postmenopausal bleeding, 27
 signs and symptoms, 26
 treatment options, 27–33
 combined oral
 contraceptives, 30
 GnRH agonists, 27, 30–1
 IV estrogen, 33
 medical, 27–30
 progestin-only
 therapy, 31–2
 surgical management, 33
 tranexamic acid, 33
 VTE risk, 33
 take home points, 34
 acquired lymphatic
 anomaly, 126
 acupuncture, for treatment of
 vasomotor
 symptoms, 96, 187
 adnexal mass, *see* pelvic mass.
 Alliance for Fertility
 Preservation, 16
 alopecia, chemotherapy
 and, 248
 Alzheimer's disease, 87
 American Joint Committee on
 Cancer (AJCC)
 classification of tumor
 size, 294
 clinical assessment of
 regional lymph
 nodes, 294
 clinical staging groups, 295
 anal and colorectal cancer,
 200–11
 case study, 200, 201,
 211
 classification, 203, 204
 diagnostic evaluation,
 202
 epidemiology, 200–1
 gynecological problems
 following chemotherapy,
 208–9
 following pelvic radiation,
 206–7
 following surgery, 207–8
 prevention and treatment,
 209–11
 ovarian toxicity, 210
 uterine toxicity, 210
 vaginal toxicity, 209–10
 screening for, 209
 hereditary risk factors, 200
 presentation, 202
 treatment, 202–5, 205
 take home points, 211
 anti-mullerian
 hormone (AMH)
 as measure of ovarian
 reserve, 4
 decreased by destruction of
 follicles, 7
 antral follicle count (AFC)
 definition, 2
 determining, 2
 normal range, 2
 assisted reproductive
 technology (ART),
 13–16
 cryopreservation of ovarian
 tissue, 13–14
 oocyte and/or embryo
 cryopreservation,
 13
 safety
 gonadotropin exposure
 and timing of
 subsequent
 pregnancy, 15–16
 ovarian stimulation, 15
 autoimmune polyendocrine
 syndrome (APS)
 type I, 84
 Bartholin's gland abscess, 120
 β -hCG elevation false-positives,
 132–42
 case study, 132, 142
 diagnostic algorithm, 140,
 141
 epidemiology and
 background, 132–4
 laboratory causes
 antibody formation
 against β -hCG, 135
 heterophilic antibodies,
 134–5
 neoplastic causes, 137–40
 germ-cell tumors, 137
 gestational trophoblastic
 disease and
 associated
 disorders, 137
 non-gynecologic
 malignancies,
 137–40
 CNS and head-and-
 neck, 140
 gastrointestinal
 carcinomas, 139
 pulmonary lesions and
 malignancies, 139

Index

- sarcoma, 139
- thyroid malignancies, 138–9
- non-neoplastic causes, 135–6
- end-stage renal disease, 136
- exogenous hCG injection, 136
- familial β -hCG, 136
- pituitary β -hCG production, 135–6
- take home points, 142
- bladder cancer, 215
- barriers to delivery of care in women with, 222
- case study, 215, 223
- diagnostic evaluation, 216
- epidemiology, 215
- gender-based disparities, 219–20
- gynecologic organ sparing ovarian preservation, 220–1
- role of, 220
- vaginal preservation, 221
- microscopic hematuria algorithm, 217
- post-surgery survivorship, 222
- presentation, 215
- staging of primary tumors, 216
- treatment, 216, 218–19
- take home points, 223–4
- blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES), 84
- BRCA pathogenic variants
 - contraceptive decisions, 102
 - early surgical menopause and, 355
 - hormonal contraception and, 102–3
 - incidence of in general and high risk populations, 43
 - lifetime risk of breast cancer, 40, 45
 - lifetime risk of selected cancer, 45, 347
 - neoadjuvant chemotherapy and, 244
 - pregnancy and, 153
 - prophylactic mastectomy and, 233, 250
 - screening/testing recommendations, 39, 43, 190, 247
 - suitability for HRT, 100
 - surgical recommendations, 86, 100, 356
 - see also* hereditary cancer syndromes.
- breast cancer, 227–51
 - and pregnancy, 148–54
 - outcome and safety of interrupting therapy, 16
 - surgical management, 152
- and research assessing GnRH agonists as a fertility-protecting agent, 12
- anti-estrogen therapy and, 61
- benign to invasive continuum, 229
- biomarkers, 229–30
- case study, 227, 250
- common treatments and newer agents, 242
- concerns for lymphoma survivors, 166
- contraception and, 102
- diagnostic workup, 230
- epidemiology, 227–8
- ER+ HER2- breast cancer
 - adjuvant chemotherapy, 239
 - adjuvant endocrine therapy, 240–1
 - metastatic disease, 241
 - neoadjuvant chemotherapy, 238–9
- fertility preservation and the “flare effect”, 12
- fertility preservation and timing of conception, 248
- HBOC-associated, 44
- HER2+ breast cancer, 245
 - early localized disease, 245
 - metastatic disease, 245–6
- hereditary breast cancer, 246–7
- adjuvant treatment considerations, 247–8
- hormonal contraceptive methods and, 30, 34, 102
- HRT and, 45, 95, 98, 264
- inflammatory breast cancer, 246
- lifetime risk
 - selected populations, 40
 - women with BRCA1/BRCA2 pathogenic variants, 40, 45
- managing VMS in women with a history of, 98
- non-hormonal therapy recommended for women with a history of, 98
- pathology, 228–9
- progestin-only hormone therapy
 - contraindicated in, 31
- prophylactic mastectomy, 233, 247
- radiotherapy
 - contraindications, 235
 - early stage breast cancer, 234–6
 - locally advanced breast cancer, 236–7
 - toxicity and developing technology, 237–8
- resources targeted at needs of young women with, 16
- risk factors, 227
- screening, 228, 247
 - gynecologic cancer survivors, 190
- staging, 230, 231
- surgical management, 230–3
 - in pregnancy, 152
 - lymph nodes, 233–4
 - psychological effects, 248
- survival rates, 179
- survivorship care, 183, 249
- systemic therapy, 238
- testosterone therapy
 - contraindicated in women with history of, 95
- treatment, 180, 230

Index

- breast cancer (cont.)
 - special considerations, 248–9
 - triple negative breast cancer
 - advanced metastatic disease, 244–5
 - neoadjuvant chemotherapy, 244
 - vaginal androgens and, 67
 - vaginal estrogen and, 65, 66, 68, 97
 - vaginal testosterone and, 68
 - take home points, 250–1
 - breastfeeding
 - breast cancer survivors and, 154
 - cervical cancer and, 161
 - chemotherapy and, 153, 172
 - diagnostic biopsy of the breast and, 151
 - from a breast treated with lumpectomy and radiation, 154
 - imaging and, 150
 - leukemia survivors, 171
 - lymphoma survivors, 167
 - postpartum radiation and, 153
 - RAI therapy and, 369, 378
 - thyroid cancer treatment and, 376
 - cancer treatment, 60
 - modalities, 2
 - potential impact on fertility, 2, 154
 - cardiovascular disease (CVD), increased risk in surgical menopause, 95
 - cardiovascular health, ABCDEs, 192
 - cervical cancer, 258–66
 - and pregnancy, 154–62
 - see also under* pregnancy, cervical cancer and.
 - case studies, 107, 114, 258, 266
 - diagnosis and workup, 261–2
 - diagnostic tests, 261
 - imaging, 261
 - physical exam, 261
 - signs and symptoms, 261
 - epidemiology, 107–8, 258–60
 - etiology and risk factors, 108, 259–60
 - HPV vaccination and prevention, 109
 - HIV infection and, 109
 - in cancer survivors, 109–10, 264
 - HRT and, 264
 - incidence and long-term prognosis, 107–8, 258
 - screening, 110–12
 - ASCCP guidelines for management of abnormal results, 112, 113
 - cervical cytology (Pap test), 110
 - HPV testing, 110–11
 - patients at average risk, 111
 - patients at increased risk, 111–12
 - recommendations following cancer, 264
 - USPSTF and ACS recommendations, 111, 261
 - staging, 258, 259, 261
 - survivorship care, 180
 - treatment, 112, 262–4
 - ASCCP 2020 guideline changes, 113
 - cervical intraepithelial neoplasia, 112–13
 - chemoradiation, 263
 - colposcopy, 112
 - fertility considerations, 260–1
 - fertility sparing, 9–10
 - live birth and preterm birth rates, 162
 - options, 10, 258, 260, 262–3, 264
 - screening recommendations, 264
 - systematic review of fertility sparing surgery, 10
 - gynecological concerns during and following, 265–6
 - immunocompromised patients, 113
 - modified radical hysterectomy, 262
 - pelvic radiation therapy combined with platinum-based chemotherapy, 263
 - sexual toxicity following, 265–6, 341
 - surveillance following, 263
 - WHO call to eliminate, 107
 - take home points, 114, 266
- cervical intraepithelial neoplasia (CIN), treatment recommendations, 112–13
- cervical stenosis, management of, 10
- chemotherapy
 - anal and colorectal cancer, gynecological problems following, 208–9
 - and alopecia, 248
 - and AUB, 26
 - and breastfeeding, 153, 172
 - as potential trigger for menopause, 94
 - chemotherapy-induced neuropathy, 249
 - contraception
 - recommendations, 12
 - impact on fertility, 154
 - potential role in POI, 7, 85
 - pregnancy and, 152, 158, 163–4, 168, 169
 - proposed mechanisms for chemotherapy-induced ovarian toxicity, 7
 - reproductive effects of treatment with, 4–7, 5
 - toxic erythema of chemotherapy (TEC), 128
- chronic graft-versus-host-disease (cGVHD), genital, 127–8
- cognitive behavioral therapy (CBT), for treatment of vasomotor symptoms, 96

Index

- combined oral contraceptives,
 for treatment of
 AUB, 30
- conception, endocrine therapy
 and timing of,
 15, 248
- contraception in cancer
 patients, 101–3
- breast cancer, 102
- case study, 103
- contraceptive counseling,
 the need for, 33–4
- epidemiology, 101–3
- medical eligibility
 criteria, 101
- take home points, 103
- contraceptive use, WHO
 medical eligibility
 criteria for, 30
- Cowden syndrome, 50, 193
- cryopreservation
 oocytes and/or embryos, 13
- ovarian tissue, 13–14
- dermoscopy, 386–7
- DICER1 syndrome, 51
- ductal carcinoma in situ
 (DCIS)
 and mortality in the US, 227
- survival rates, 179
- early menopause, led to by
 conditioning
 regimens, 26
- endocrine therapy
 and timing of pregnancy,
 15, 248
- as potential trigger for
 menopausal
 symptoms, 94,
 125, 187
- efficacy, 239
- functioning, 61, 94
- hormone blocker choice and
 previous exposure
 to, 241
- risk of vaginal dryness and
 dyspareunia,
 187, 249
- sexual dysfunction and, 63
- endocrine-disrupting
 chemicals (EDCs),
 examples and
 potential impact on
 hormonal
 function, 86
- endometrial cancer, 271–8
- AUB and evaluation for, 273
- case study, 271, 278
- epidemiology, 271–3
- evaluation, 273
- genetic testing for women
 with, 46–50
- HRT and, 99–100, 278
- incidence and long-term
 prognosis, 271
- inherited cancer syndromes
 and, 274
- pathophysiology, 271–2
- risk factors, 271–3
- screening, 273
- staging, 273, 274
- survivorship care, 180
- treatment, 274–8
- advanced stage/recurrent
 disease, 275
- fertility sparing approach,
 277–7
- molecular classification
 and prognosis, 275
- radiation, 276–7
- recommendations
 following cancer
 therapy, 278
- surgical, 274
- vaginal
 brachytherapy, 276
- take home points, 278–9
- epithelial carcinomas, 352
- Fanconi's anemia, 305
- fertility
 baseline assessment, 2, 4
- ovarian reserve assessment, 3
- potential impact of cancer
 treatment on,
 2, 154
- fertility counseling, women
 diagnosed with
 cancer, percentage
 reporting not
 receiving, 1
- fertility preservation
 assisted reproductive
 technology (ART),
 13–16
- cryopreservation of
 ovarian tissue,
 13–14
- oocyte and/or embryo
 cryopreservation,
 13
- safety
 gonadotropin exposure
 and timing of
 subsequent
 pregnancy, 15–16
- ovarian stimulation, 15
- case study, 17
- conception, timing of, 248
- GnRHa
 “flare effect”, 12
- research assessing use
 of, 12
- leukemia, 311–12
- ovarian suppression,
 11–13
- resources, 16
- surgical
 ovarian transposition
 (oophoropexy), 11
- uterine transposition and
 fixation, 11
- vulvar melanoma,
 considerations
 prior to treatment,
 389–90
- take home points, 17
- fertility sparing approaches
 cervical cancer, 9–10
- live birth and preterm
 birth rates, 162
- options, 10, 258, 260,
 262–3, 264
- prior considerations,
 260–1
- screening
 recommendations,
 264
- systematic review of
 fertility-sparing
 surgery, 10
- trachelectomy, 10, 258,
 262–3
- endometrial cancer, 8–9,
 277
- ovarian cancer, 10
- ovarian suppression,
 dosing, 12
- Fragile X Syndrome (FXS),
 83
- gabapentin
 for management of
 vasomotor
 symptoms, 96
- side-effects, 96
- galactosemia, 83

Index

- genitourinary syndrome of
 menopause (GSM)
 and vaginal stenosis, 72
 as effect of induced
 menopause or
 estrogen
 blockade, 60
 as side-effect of treatment for
 vulvar lesions, 125
 post-oophorectomy estrogen
 deficiency and, 221
 treatment, 63–8
 moisturizers
 avoiding irritants, 63–4
 non-hormonal
 moisturizers, 64–5
 types and
 recommendations,
 65
 vs lubricants, 64
 pelvic floor muscle
 training
 (PFMT), 72–3
 treatment algorithm, 73
 vaginal androgen therapy,
 67, 68
 vaginal estrogen
 therapy, 65
 germ cell tumors,
 malignant, 353
 gonadotropin-releasing
 hormone (GnRH)
 agonists
 assessment of as fertility-
 protecting
 agent, 12
 common adverse side
 effects, 13
 exposure to and timing of
 subsequent
 pregnancy, 15–16
 fertility preservation through
 ovarian
 suppression, 11–13
 “flare effect”, 12
 for prevention and treatment
 of AUB, 27, 30–1
 to reduce risk of POI, 248
 gynecological cancer
 contraceptive decisions, 102
 hereditary predisposition
 syndromes, 38–54
see also hereditary cancer
 syndromes;
*individual cancer
 and syndromes.*
- third party reproductive
 options, 14
 treatment regimen, 180
see also cervical cancer;
 endometrial
 cancer; ovarian
 cancer; pelvic mass;
 vulvar lesions and
 eruptions; vulvar
 melanoma.
- Hashimoto’s disease, 85, 372
 hCG elevation false-positives,
see β -hCG
 elevation false-
 positives.
- head and neck cancer, 298
 overview, 284, 286
 case study, 284, 285,
 296–7, 297
 diagnosis and staging, 293–4
 epidemiology, 286–90
 incidence trends, 287
 left sided level II neck
 mass, 293
 sagittal view of the
 pharynx, 286
 second primary cancer
 risk, 288
 site distinctions, 286–7
 treatment and toxicities,
 294–6
 tumor size, classification
 (AJCC), 294
 take home points, 297–8
see also HPV-related
 oropharyngeal
 cancer (OPC).
- heavy menstrual bleeding,
 hematologic
 malignancies
 and, 25
 hematologic malignancies
 and the avoidance of
 menses, 12
 AUB and, 25
 presenting symptoms, 25,
 26, 167
 venous thromboembolism
 and, 33
see also leukemia.
- hematopoiesis, definition,
 304
 hereditary breast and ovarian
 cancer (HBOC)
 etiology, 44
- HBOC-associated cancer, 44
 incidence, 43
 increased breast
 surveillance, 45–6
 screening and risk reducing
 surgery for
 gynecologic
 cancer, 44–5
 hereditary cancer syndromes
 overview, 40–3
 case study, 38, 39,
 53
 common syndromes
 associated with
 gynecological
 cancer, 38
 Cowden syndrome, 50
 DICER1 syndrome, 51
 family planning
 implications, 53
 genetic testing
 overview, 38–40
 common indications
 for, 41
 for women with
 endometrial
 cancer, 46–50
 for women with ovarian
 cancer, 43–6
 interpretation of
 results, 53
 hereditary breast and
 ovarian cancer
 (HBOC)
 etiology, 44
 HBOC-associated
 cancer, 44
 incidence, 43
 increased breast
 surveillance,
 45–6
 screening and risk
 reducing surgery
 for gynecologic
 cancer, 44–5
 Li Fraumeni syndrome, 43
 Lynch syndrome
 aspirin chemoprophylaxis
 and, 50
 benefits of screening
 colonoscopy, 50
 cancer associated with,
 47, 48
 diagnosis, 47–9
 etiology, 46–7
 incidence, 46

Index

- multidisciplinary management, 50
- Prospective Lynch Syndrome Database, 47
- screening and risk reducing surgery for gynecologic cancer, 49
- Peutz-Jeghers syndrome (PJS), 51
- PTEN hamartoma tumor syndrome (PHTS), 50
- rhabdoid tumor predisposition syndrome, 50–1
- risk assessment for women with family history of cancer, 52–3
- risk factors, 39
- take home points, 54
- HIV infection
 - and HPV vaccination, 109
 - and increased risk of HPV infection, 108
 - and menstrual suppression, 32
- hormone replacement therapy (HRT)
 - overview, 95–6
 - and breast cancer, 45, 95, 98, 264
 - and cervical cancer, 264
 - and endometrial cancer, 99–100, 278
 - following hysterectomy, 278
- as treatment for POI-related symptoms, 88
- as treatment for vasomotor symptoms, 95
- contraindications, 264
- for menopause in cancer patients
 - administration of, 95–6
 - duration of use, 96
 - indications for avoidance, 98
 - indications for caution, 99–100
 - indications for use, 97–8
 - suitability by cancer type, 99
- ovarian cancer and, 355–6
- suitability for patients with lung cancer, 100
- suitability for patients with Lynch syndrome, 100
- suitability for patients with malignant melanoma, 100
- suitability for women with BRCA diagnosis, 100
- HPV vaccination
 - ACIP recommendations, 191
 - and prevention of cervical cancer, 109
 - CDC recommendations, 109
 - HIV and, 109
 - in cancer survivors, 109–10, 264
 - prevention of HPV-related OPC, 290
 - see also* human papillomavirus (HPV).
- HPV-related oropharyngeal cancer (OPC)
 - overview, 286
 - behavioral risk factors, 288
 - clinical presentation, 292
 - demographic characteristics, 287
 - diagnosis and staging, 293–4
 - incidence trends, 287
 - pregnancy and, 296
 - prevention and screening, 290–2
 - blood biomarkers, 291
 - ongoing trials, 291
 - oral HPV testing, 290–1
 - risk stratification for screening selection, 292
 - screening for second HPV-related cancer in patients and partners, 296
 - vaccination, 290
 - risk for partners of patients with, 289
 - risk in patients with cancer at anogenital sites, 289
 - second primary cancer risks, 288
 - treatment and toxicities, 294
 - take home points, 297–8
- human chorionic gonadotropin (hCG) *see* β -hCG elevation false-positives.
- human papillomavirus (HPV)
 - overview, 108
 - anal cancer associated with, 201
 - as risk factor for lung cancer, 334
 - HIV infection and increased risk of infection with, 108
 - HPV in Men (HIM) study, 291
 - multi-national natural history study, 291
 - reactivation under chronic immuno suppression, 128
 - screening issues, 51
 - testing for, 110–11
 - see also* cervical cancer; HPV vaccination; HPV-related oropharyngeal cancer (OPC).
- hypnosis, for treatment of vasomotor symptoms, 96, 187
- hysterectomy
 - cervical cancer and, 158, 258, 262
 - endometrial cancer and, 273, 274
 - alternatives, 271, 277
 - HRT, 278
 - Lynch syndrome and, 49, 86, 272, 274
 - malignant pelvic masses and, 351
 - opportunistic salpingectomy at time of, 220
 - PHTS and, 50
 - PJS and, 51
 - radical, 262, 262
 - long-term side effects, 265
 - recommended for ovarian cancer patients following completion of childbearing, 10
 - risk reducing, age and, 49, 51
 - risks, 158

Index

- hysterectomy (cont.)
 minimally invasive approaches, 221
 RTPS and, 51
 screening recommendations following, 112
 uterine cancer and, 273
- immune-checkpoint inhibitor cutaneous toxicities, 128
- immunotherapy, reproductive effects of treatment, 8
- intrauterine devices, AUB and, 26
- Kaposi's sarcoma (KS), 121
- leukemia
 overview, 304
 acute leukemias, 304–17
 definition, 304
 case study, 304, 316
 epidemiology, 305
 acute lymphoblastic leukemia (ALL)
 B-cell ALL, 309
 T-cell ALL, 309
 pregnancy and, 314–16
 acute myeloid leukemia (AML)
 pregnancy and, 313–14
 risk stratification, 307, 308
 gynecologic/obstetric considerations, 309–16
 AUB, 310–11
 cytopenias in patients with history of platinum-based therapy, 310
 fertility preservation, 311–12
 pregnancy, 312–16
 ALL, 314–16
 AML, 313–14
 long-term considerations, 307
 management, 306–7
 pathophysiology, 304–5
 presentation and evaluation, 306
 take home points, 316–17
- and pregnancy, 167–72
 see also under pregnancy, leukemia and.
- chronic leukemias, 317–23
 overview, 304
 chronic lymphocytic leukemia (CLL), 323
 case study, 319, 323
 epidemiology and pathophysiology, 319–20
 evaluation and prognosis, 320, 321
 management, 321–2
 special considerations, 322–3
 staging systems, 321
 take home points, 323
 chronic myeloid leukemia (CML), 317–19
 case study, 317, 319
 epidemiology and pathophysiology, 317
 management, 318
 phases, 318
 pregnancy and, 318
 presentation and evaluation, 317–18
 take home points, 319
- ovarian tissue transplantation not recommended, 14
- lichen planus (LP), 123–4
- lichen sclerosus (LS), 122–3
 association with vulvar melanoma in pediatric patients, 383, 384
- lichen simplex chronicus (LSC), 124–5
- Li-Fraumeni syndrome, 193
- Livestrong Fertility, 16
- lung cancer, 331–42
 biomarkers, 337, 338
 liquid biopsy, 337
 molecular markers, 337
 prognostic factors associated with good outcomes, 337–8
 tumor PD-L1 expression, 337
 case study, 331, 342
 classification, 332
- epidemiology, 331–2
 imaging, 335–6
 risk factors, 332–5
 cigarette smoking, 332
 cooking oil fumes, 333
 environmental tobacco smoke, 333
 genetic, 334
 hormonal, 333
 indoor coal and wood burning, 333
 infection, 334
 radiation therapy, 335
 radon, 333
 screening, 335
 sex-based differences, 331, 341
 outcomes of surgical resection, 339
 risk factors, 333
 side-effects of systemic therapy, 339
 staging, 338
 suitability of HRT for patients with, 100
 survivorship, 340–2
 cancer-related fatigue, 340
 ICI therapy, 341
 pregnancy, 340–1
 reproductive health, 340
 sexual health, 341
 sleep disturbance, 341
 symptom clusters, 341
 therapy-related complications, 341
 symptoms, 335
 treatment, 338–40
 metastatic disease, 339–40
 neoadjuvant and adjuvant therapy, 339
 oligometastatic disease, 340
 radiotherapy, 339
 surgery, 338–9
 take home points, 342
- lymph nodes, clinical assessment (AJCC), 294
- lymphatic anomaly, acquired, 126
- lymphedema, risk factors, 249
- lymphoma, and pregnancy, *see also under* pregnancy, lymphoma and, 162–7

Index

- Lynch syndrome
 and POI, 86
 aspirin chemoprophylaxis
 and, 50
 benefits of screening
 colonoscopy, 50
 cancer associated with, 47,
 48
 diagnosis, 47–9
 etiology, 46–7
 hysterectomy and, 49, 86,
 272, 274
 incidence, 46
 lifetime risk of endometrial
 and colon
 cancer, 272
 multidisciplinary
 management, 50
 ovarian cancer, screening
 recommendations,
 274
 Prospective Lynch
 Syndrome
 Database, 47
 risk factors, 192
 risk reducing surgery
 recommended for
 patients with, 356
 RRSO and, 274
 screening and risk reducing
 surgery for
 gynecologic
 cancer, 49
 suitability for HRT, 100
- malignant germ cell
 tumors, 353
- malignant melanoma,
 suitability for
 HRT, 100
- melanoma, ABCDEs of, 386
- menopause in cancer patients,
 93–101
 case study, 93, 100
 diagnosis, 94
 epidemiology, 93–4
 HRT
 administration of, 95–6
 duration of use, 96
 indications for
 avoidance, 98
 indications for caution,
 99–100
 indications for use, 97–8
 suitability by cancer
 type, 99
- non-hormonal
 pharmacotherapy,
 96–7
- non-pharmacological
 treatments for
 symptoms, 96
- pre-treatment
 considerations, 94
- site specific
 considerations, 97
- treatment, 94
- urogenital symptoms, 97
- take home points, 100
- menopause, definition, 93
- menstrual bleeding, heavy,
 hematologic
 malignancies
 and, 25
- menstrual cycle
 normal, 25
 phases, 25
- menstrual suppression, 12, 17,
 27, 31, 32, 322
- neurokinin receptor
 antagonists, for
 management of
 vasomotor
 symptoms, 97
- neuropathy, chemotherapy-
 induced, 249
- obesity, and endometrial
 cancer, 46
- Oncofertility Consortium, 16
- oocyte and/or embryo
 cryopreservation,
 13
- oophoropexy, 11
- ovarian cancer, 352–6
 overview, 352
 case study, 346, 356
 clinical presentation, 352
 contraception and, 355–6
 epithelial carcinomas, 352
 fertility sparing approach,
 10
 genetic considerations, 356
 genetic testing for women
 with, 43–6
 histologic subtypes, 352
 HRT and, 355–6
 hysterectomy recommended
 following
 completion of
 childbearing, 10
- malignant germ cell
 tumors, 353
 prognosis, 355
 screening, 356
 sex cord stromal tumors,
 353
 staging, 353, 354
 suitability for HRT, 100
 survivorship care, 183
 treatment, 354–5
 take home points, 356–7
see also pelvic mass.
- ovarian hyperstimulation
 syndrome, as
 complication of
 ART, 13
- ovarian preservation, as
 pre-cancer
 treatment
 consideration, 94
- ovarian reserve
 overview, 2
 assessment, 3
 diminished, presentation, 7
 hormonal measures, 4
 testing methods, 2
- ovarian stimulation, safety
 considerations,
 15
- ovarian suppression therapies,
 11–13
 dosing, 12
- ovarian tissue
 cryopreservation of, 13–14
 potential for infiltration
 of malignant
 cells, 14
- ovarian toxicity, proposed
 mechanisms for
 chemotherapy-
 induced, 7
- ovarian transposition for
 preservation of
 fertility
 (oophoropexy), 11
- pelvic floor muscle training
 (PFMT), 72–3
- pelvic floor physical
 therapy, 187
- pelvic mass, 346–52
 case study, 346, 356
 diagnosis and workup,
 347–9
 diagnostic tests, 348
 imaging, 348–9

Index

- pelvic mass (cont.)
 O-RADS Risk
 Stratification
 System, 350
 physical exam, 348
 serum tumor markers, 348
 signs and symptoms, 347
 epidemiology, 346–7
 etiology and risk factors, 346–7
 incidence and long-term prognosis, 346
 surveillance, 351–2
 treatment options, 351
 benign masses, 351
 masses concerning for malignancy, 349–51
 masses requiring prompt attention, 349
 surgical approach and procedure, 351
 take home points, 356–7
 see also ovarian cancer.
- Perrault syndrome, 83
 Peutz-Jeghers syndrome (PJS), 51
- pregnancy
 and thyroid cancer, 376–7
 best avoided during cancer treatment, 101
 breast cancer and, 148–54
 case study, 147, 172
 diagnosis and workup
 diagnostic studies for pregnant and lactating women, 150
 diagnostic tests, 151
 differential diagnosis, 148, 149
 imaging, 148–50
 physical exam, 148
 signs and symptoms, 148
 staging, 151
 epidemiology, 148
 obstetric management
 antenatal testing, 153
 breastfeeding, 150, 153
 delivery route and timing, 153
 fetal risk, 150, 151, 153
 maternal risk, 152
- survivors of breast cancer, 153–4
 treatment, 151–2
 chemotherapy, 152, 158, 163–4, 168, 169
 delay of, 152
 radiation, 151–2
 surgery, 152
- cancer and, 147–73
 definition of cancer during pregnancy, 147
 pregnancy following remote history of anthracycline use, 172
 take home points, 173
- cervical cancer and, 154–62
 diagnosis and workup, 157
 differential diagnosis, 155
 evaluation of abnormal cervical biopsy, 156
 evaluation of abnormal cytology, 156
 physical exam, 155–6
 signs and symptoms, 155
 staging, 156
 epidemiology, 154–5
 obstetric management, 158–61
 antenatal testing, 160
 breastfeeding, 161
 delivery route and timing, 159, 160–1
 fetal risk, 157, 160
 maternal risk, 158
- survivors of cervical cancer, 161–2
 treatment, 157
 chemotherapy, 158
 delay of, 155, 158
 fertility sparing, live birth and preterm birth rates, 162
 options, mode and timing of delivery, 159, 160–1
 radiation, 157
 surgery, 158
 termination, 157, 158
- endocrine therapy and timing of, 15, 248
 following lung cancer survivorship, 340–1
- gonadotropin exposure and timing of, 15–16
- leukemia and, 167–72
 acute leukemia during pregnancy, 312–16
 CML, special considerations, 318
 diagnosis and workup, 168
 signs and symptoms, 167
 staging, 167
 epidemiology, 167
 obstetric management
 antenatal testing, 170
 breastfeeding, 170
 delivery route and timing, 170
 fetal risk, 170
 maternal risk, 170
 survivors of leukemia, 171–2
 treatment, 168–70
 chemotherapy, 168, 169
 delay of, 168–70
 radiation, 168
 stem cell transplantation, 168
 termination, 168
- lymphoma and, 162–7
 diagnosis and workup, 163
 physical exam, 163
 signs and symptoms, 162
 staging, 163
 epidemiology, 162
 obstetric management, 166
 antenatal testing, 164
 breastfeeding, 166
 delivery route and timing, 166
 fetal risk, 163, 164
 maternal risk, 164
 survivors of lymphoma, 166–7
 treatment, 163–4
 chemotherapy and immunotherapy, 163–4
 delay of, 164
 radiation, 163
 termination, 163
 trimester-stratified options for, 165

Index

- radiotherapy
 - contraindicated during, 8
- premature ovarian insufficiency (POI), 81–9
 - as consequence of conditioning regimens, 26
 - as potential outcome of chemotherapy, 7, 85
- autoimmune etiologies, 84–5
- case study, 81, 89
- definition, 81
- environmental and social risk factors, 86
- epidemiology, 81–7
- ethnicity and, 86
- etiology, 82–7
- first-line treatment, 88
- genetic risk factors, 82–4
- health consequences, 86–7
- iatrogenic risk factors, 85–6
- incidence and long-term prognosis, 81–2
- increased prevalence in cancer patients, 82
- laboratory evaluation, 82
- radiotherapy dose inducing, 7
- reproductive implications, 87–8
- resulting from acute leukemia treatment, 312
- take home points, 89
- progestin-only therapy, for treatment of AUB, 31–2
- pseudo-hypoparathyroidism type 1a, 84
- PTEN hamartoma tumor syndrome (PHTS), 50
- radiation dermatitis, 126–7
- radiation recall, 127
- radiation, histological changes following, 8
- radiotherapy
 - and vaginal stenosis, 187, 265
 - as trigger for menopause, 94
 - potential role in POI, 85
 - reproductive effects of treatment, 7–8
- uterine, potential impact on the fetus, 8
- vaginal brachytherapy for treatment of endometrial cancer, 276
- reflectance confocal microscopy (RCM), 387
- reproductive effects of treatment
 - chemotherapy, 4–7, 5
 - proposed mechanisms for chemotherapy-induced ovarian toxicity, 7
- immunotherapy, 8
- radiotherapy, 7–8
- rhabdoid tumor predisposition syndrome, 50–1
- risk reducing salpingo-oophorectomy (RRSO)
 - as trigger for surgical menopause, 94, 355
- Lynch syndrome and, 274
- recommendations for patients at risk of developing gynecological cancer, 44, 46, 86, 356
- SaveMyFertility, 16
- selective serotonin reuptake inhibitors (SSRIs), for treatment of vasomotor symptoms, 96, 187
- serotonin noradrenaline reuptake inhibitors (SNRIs), for treatment of vasomotor symptoms, 96
- Sertoli-Leydig cell tumor (SLCT), 51
- sex cord stromal tumors, 353
- sexual health management, 60–75
 - anti-estrogen therapies and, 61–3
 - bioidentical hormones, 68–9
 - case study, 60, 74
 - dyspareunia, 70
- etiology of concerns in female cancer patients, 60–1
- genitourinary syndrome of menopause
 - moisturizers
 - avoiding irritants, 63–4
 - non-hormonal moisturizers, 64–5
 - types and recommendations, 65
 - vs lubricants, 64
- pelvic floor muscle training (PFMT), 72–3
- treatment, 63–8
- treatment algorithm, 73
- vaginal androgen therapy, 67, 68
- vaginal estrogen therapy, 65
- vaginal stenosis, 72
- low desire during and following cancer treatment, 73–4
- moisturizers, lubricants, and sexual devices, 71
- pelvic floor muscle training (PFMT), 72–3
- POI and, 87
- survivorship care, 187–9, 265–6, 341
- vaginal androgen therapy, 67–8
- vaginal estrogen therapy, 65–7
- vaginal laser therapy, 69–70
- vaginal stenosis, 72
- take home points, 74–5
- staging, clinical groups (AJCC), 295
- Stupid Cancer, 16
- survivorship care, 179–96
 - bladder cancer, post-surgery, 222
 - bone health, 183–7
 - breast cancer, 183, 249
 - and breastfeeding, 154
 - case study, 179, 196
 - cervical cancer, 180
 - core domains, 180
 - endometrial cancer, 180
 - epidemiology and background, 179
 - following lung cancer, 340–2

Index

- survivorship care (cont.)
 pregnancy, 340–1
 ovarian cancer, 183
 psychosocial functioning
 body image, 195
 distress management,
 193–5
 financial stressors, 196
 social support, 196
 risk reduction and early
 detection, 189–92
 cancer screening, 190–1
 cardiovascular health,
 192
 cardiovascular health,
 ABCDEs, 192
 genetic screening, 192–3
 hepatitis screening, 191
 HPV vaccination, 191
 lifestyle assessment,
 189–90
 sexual function, 187–9
 surveillance and monitoring
 for late effects,
 179–80
 take home points, 197
 Swyer Syndrome, 83
- thrombocytopenia
 and avoidance of menses,
 12
 AUB and, 25–6
 exacerbated by TBI, 26
 thyroid cancer, 362–78
 case study, 362, 377–8
 epidemiology, 362–3
 hereditary cancer syndromes
 associated
 with, 375
 nodule evaluation, 365–6
 ATA guidelines, 366
 Bethesda System, 368
 TI-RADS classification
 system, 367
 non-thyroid origin
 malignancies,
 372–3
 metastasis to the thyroid
 gland, 372
 struma ovarii, 373
 thyroid lymphoma, 372–3
 overview of the thyroid
 gland, 363–4, 365
 synthesis and secretion of
 thyroid hormones,
 363–4
- thyroid hormone
 action, 364
 pathophysiology, 368–72
 anaplastic thyroid
 cancer, 371
 differentiated thyroid
 cancer, 368
 staging, 369
 follicular thyroid
 carcinoma, 370
 Hürthle cell
 carcinomas, 370
 medullary thyroid cancer,
 371–2
 papillary thyroid cancer,
 368–70
 poorly differentiated
 thyroid cancer,
 370
 undifferentiated thyroid
 cancer, 371–2
 pregnancy and, 376–7
 risk factors, 373
 benign thyroid disease,
 373
 genetic, 374
 gynecologic, 374–6
 ionizing radiation, 373
 surveillance, 377
 take home points, 378
 total body irradiation (TBI),
 thrombocytopenia
 exacerbated by, 26
 toxic erythema of chemotherapy
 (TEC), 128
 trachelectomy
 as fertility sparing approach
 to cervical cancer,
 10, 258, 262–3
 cerclage placed at time of or
 following, 160
 hemorrhage risk and
 pregnancy loss
 rate, 158
 live birth and preterm birth
 rates, 162
 post-procedure infertility
 rates, 10
 tumor size, classification
 (AJCC), 294
 Turner Syndrome, 82
 uterine transposition and
 fixation, for
 preservation of
 fertility, 11
- vaginal atrophy,
 see also
 genitourinary
 syndrome of
 menopause
 (GSM). 60
 vaginal stenosis
 management, 72
 radiation therapy and,
 187, 265
 vasomotor symptoms (VMS)
 experienced by survivors of
 gynecological
 cancer, 187
 HRT for management
 of, 97–8
 non-hormonal medications
 for management
 of, 96–7
 venous thromboembolism
 (VTE)
 increased risk with HRT, 95
 risk of for cancer patients, 33
 vulvar lesions and eruptions,
 117–29
 vulvar skin and mucosa,
 overview, 118
 biopsy considerations,
 118–19
 case study, 117, 117, 128
 general vulvar care, 118
 infections
 abscesses and furuncles,
 120–1
 angioinvasive, 121
 candidal, 121–2
 folliculitis, 119–20
 herpes virus, 121
 varicella zoster virus, 121
 vulvar candidiasis, 122
 primary inflammatory
 dermatoses
 lichen planus, 123–4
 lichen sclerosus, 122–3
 lichen simplex chronicus,
 124–5
 terminology, 117
 topical steroid ointments, 119
 treatment side effects
 acquired lymphatic
 anomaly, 126
 genital chronic graft-
 versus-host-disease
 (cGVHD), 127–8
 genitourinary syndrome
 of menopause, 125

Index

immune-checkpoint inhibitor cutaneous toxicities, 128 radiation dermatitis, 126–7 radiation recall, 127 toxic erythema of chemotherapy, 128 vulvar lymphedema, 126 take home points, 129 <i>see also</i> vulvar melanoma. vulvar lymphedema, 126 vulvar melanoma, 383–90 overview, 383, 390 case study, 383, 390 diagnosis and workup, 385–7 ABCDEs of melanoma, 386 common dermatologic terms, 385	dermoscopy and in vivo reflectance confocal microscopy, 386–7 diagnostic tests, 386 differential diagnosis, 386 histopathology, 387 physical exam, 385 epidemiology, 383–4 etiology and risk factors, 384 incidence and long-term prognosis, 383–4 pathogenesis, 385 pediatric patients, 383, 384 prognosis, 383, 388 reproductive considerations, 389–90 staging, 388 surveillance/screening, 390	treatment, 388–9 take home points, 390 women diagnosed with cancer age, 1 guidelines on discussing the risk of infertility and fertility preservation options, 1 number of in 2020, 1 percentage of reproductive age, 1 percentage reporting not receiving fertility counseling, 1 yoga, for treatment of vasomotor symptoms, 187 Young Survival Coalition, 16
--	---	--